Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The largest peer-reviewed study of the Pfizer-BioNTech COVID vaccine in cancer patients finds no more, and no different, side effects.
An NIH-sponsored study assessed boosters for adults fully vaccinated with any authorized or approved COVID-19 vaccine.
Paxlovid dramatically reduced the risk of severe illness and death, but it must be started soon after developing symptoms.
Vaccine effectiveness for children ages 5 to 11 was 91%, and serious side effects are rare.
People with blood cancers and those on chemotherapy may not respond adequately to their first two vaccine doses.
Many people who received any of the authorized COVID-19 vaccines are now eligible for an additional dose of their choice.
Third booster dose may improve immune response in cancer patients without sufficient protection after second dose.
Third dose OK’d for people over 65, those at risk for severe COVID-19 and those at high risk of exposure to the coronavirus.
Natural immunity and vaccine responses may be weaker in people with immune suppression, so they should get their second dose promptly.
Another vaccine, from Novavax, was 89% effective in a U.K. trial, but both were less potent against the South African coronavirus mutation.
A slow vaccine rollout and the emergence of new coronavirus mutations threaten progress in reducing new cases and death.
The technology used in COVID-19 vaccines may also be used to prevent other viral infections and to treat cancer and multiple sclerosis.
Pfizer-BioNTech’s coronavirus vaccine is 95% effective for preventing symptomatic illness.
The front-runner coronavirus vaccine appears to protect people from symptomatic disease.
Four vaccine candidates produced antibody and T-cell immune responses in the first stages of human clinical trials.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.